Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Shares Outstanding for 8 consecutive years, with $28.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 4.86% year-over-year to $28.4 million, compared with a TTM value of $28.4 million through Dec 2025, up 4.86%, and an annual FY2025 reading of $28.4 million, up 4.86% over the prior year.
  • Shares Outstanding was $28.4 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $27.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $28.4 million in Q4 2025 and bottomed at $26319.0 in Q1 2021.
  • Average Shares Outstanding over 5 years is $24.2 million, with a median of $26.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding skyrocketed 100771.96% in 2023, then tumbled 99.9% in 2025.
  • Year by year, Shares Outstanding stood at $26.4 million in 2021, then increased by 0.69% to $26.6 million in 2022, then rose by 1.03% to $26.8 million in 2023, then grew by 1.0% to $27.1 million in 2024, then grew by 4.86% to $28.4 million in 2025.
  • Business Quant data shows Shares Outstanding for ARCT at $28.4 million in Q4 2025, $27.2 million in Q3 2025, and $27.1 million in Q2 2025.